|
[1] 石旦,徐斌,蒋敬庭.MELK mRNA表达水平在非小细胞肺癌患者中的预后价值[J].临床检验杂志,2020,38(5):389-394.
DOI:10.13602/j.cnki.jcls.2020.05.18.
[2] 中国抗癌协会肺癌专业委员会,中华医学会肿瘤学分会肺癌学组,中国胸部肿瘤研究协作组.Ⅰ~ⅢB期非小细胞肺癌完全切除术后辅助治疗指南(2021版)[J].中华医学杂志,2021,101(16):1132-1142.
DOI:10.3760/cma.j.cn112137- 20210210-00406.
[3] 姚望,罗斌,田建辉.免疫衰老与肿瘤发病机制[J].中国肿瘤临床,2019,46(13):686-689. DOI:10.3969/j.issn.1000- 8179.2019.13.743.
[4] Brody R, Zhang Y, Ballas M, et al. PD-L1
expression in advanced NSCLC: insights into risk stratification and treatment
selection from a systematic literature review[J]. Lung Cancer, 2017,
112:200-215. DOI: 10.1016/j.lungcan.2017.08.005.
[5] Tamura H, Ishibashi M, Sunakawa-Kii M,
et al. PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma[J].
Cancers (Basel), 2020, 12(4):924. DOI: 10.3390/cancers12040924.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111. DOI:10.3969/j.issn.1671- 5144.2004.02.012.
[7] 郑子烨,王颖轶.PD-1/PD-L1抑制剂在肿瘤治疗中的研究进展[J].山东医药,2019,59(25):97-100.
[8] Fu L, Wang R, Yin L, et al. CYFRA21-1
tests in the diagnosis of non-small cell lung cancer: a meta-analysis[J]. Int J
Biol Markers, 2019, 34(3):251-261. DOI: 10.1177/1724600819868234.
[9] 杨颖,夏曙,何肇晴,等.血清CA125、Cyfra21-1和VEGF水平在非小细胞肺癌患者放化疗敏感性和预后评估中的应用价值[J].实用癌症杂志,2019,34(6):940-943.
DOI:10.3969/j.issn.1001-5930.2019.06.020.
[10] Nangia-Makker P, Hogan V, Raz A.
Galectin-3 and cancer stemness[J]. Glycobiology, 2018, 28(4):172-181. DOI:
10.1093/glycob/cwy001.
[11] 齐德林,张毅,李洪利,等.Galectin-3在非小细胞肺癌患者血清中的表达及其临床意义[J].中国肺癌杂志,2020,23(5):333-336.
DOI:10.3779/j.issn.1009-3419.2020.102.03.
[12] 王芸,王郁阳,姜曼,等.帕博利珠单抗对晚期非小细胞肺癌患者T淋巴细胞亚群的影响及疗效观测[J].中国肺癌杂志,2021,24(3):182-187. DOI:10.3779/j.issn.1009-3419. 2021.103.03.
|
